An exploratory, open label, non-randomized, within-patient multiple dose-escalation safety, tolerability, PK and efficacy trial of RAD001 (everolimus) in patients with Lymphangioleiomyomatosis.

Registry ID

EUCTR2010-019825-32

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

NOVARTIS FARMA

Start date

2010-07-28

Last update

2026-08-16

Conditions

• Lymphangioleiomyomatosis

Summary

The primary objective is to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD, assessed by serum VEGF-D) of everolimus in patients with lymphangioleiomyomatosis (LAM).

Locations

• , , France
• , , Italy

Related clinical trials

• Study of the Disease Process of Lymphangioleiomyomatosis
• Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
• TSC Biosample Repository and Natural History Database
• Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
• Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
• National Lymphangioleiomyomatosis Registry, France

View on source registry